All peptide injections caused phase-dependent phase shifts of hamster locomotor activity rhythms which were unaffected by constant lighting conditions. GRP,,, (150 pmol) caused large phase delays when injected at circadian times (CT) 12-16, modest phase advances when administered at CT20-24, and few shifts during the subjective day. Injections of saline vehicle at any of these phases caused only very small phase shifts. Phase delays induced by GRP,,, at CT12-14 were dose dependent, unrelated to injection volume (at a constant dose), and attenuated by pretreatment with the BNIGRP-preferring receptor antagonist BIM 26226. VIP (150 pmol) caused moderate phase delays at CT12-14 and moderate phase advances at CT20-24. PHI (150 pmol) caused moderate phase delays at CT12-14 only. Coadministration of 150 pmol of GRP,,,, PHI, and VIP in an equimolar neuropeptide cocktail (50 pmol of each peptide) caused phase delays at CT12-14 and phase advances at CT20-24 which did not differ from those induced by 150 pmol of GRP,,, alone at these phases. The shifts induced by 150 pmol of the peptide cocktail were smaller than the sum of the shifts induced by 50 pmol doses of each peptide administered separately at those phases. Since the phase-delaying effects of the cocktail were weaker than the summed effects of the component 50 pmol doses of the peptides, these data demonstrate a lack of synergism among the effects of these peptides. Since GRP,-,, (150 pmol) evoked shifts similar in magnitude to those of the cocktail, there is no evidence that these apparently colocalized neuropeptides must interact to exert maximal effects on the circadian pacemaker. Colocalization of neuroactive substances in single neurons has been demonstrated in many parts of the central and peripheral nervous systems. Although direct evidence for the functional implications of this phenomenon is rare, it has been proposed that colocalized neuropeptides can interact to modulate neuroactivity. This interaction may take many forms, including (but not limited to) modulation by one substance of postsynaptic receptor responses to another, inhibition of catabolic enzymes, presynaptic regulation by one substance of the release of other neurotransmitters, and alterations in presynaptic reuptake mechanisms (Kupfermann, 1991; Bean et al., 1994) .
One area of the hypothalamus in which neuropeptides are thought to be colocalized is the suprachiasmatic nucleus (SCN). The SCN contains the primary mammalian circadian pacemaker (Rusak and Zucker, 1979; Meijer and Rietveld, 1989) . This pacemaker is entrained by photic information received through the visual pathways innervating the SCN, the retinohypothalamic tract (RHT) (Moore, 1973; Pickard, 1982; Johnson et al., 1988) , and the geniculohypothalamic tract (GHT) (Swanson et al., 1974; Harrington and Rusak, 1986; Zhang and Rusak, 1989) .
Both immunocytochemical and in situ hybridization studies indicate that cells and terminals of the rodent SCN contain a number of neuropeptides including gastrin-releasing peptide (GRP,,,), peptide histidine isoleucine (PHI), somatostatin, substance P, vasoactive intestinal polypeptide (VIP), and vasopressin (VP) (Lorkn et al., 1979; Moody et al., 1981; Roth et al., 1982; Card and Moore, 1984; Panula et al., 1984; Okamura et al., 1986; van den Pol and Gores, 1986; Wada et al., 1989; Dussaillant et al., 1992; Gundlach and Knobe, 1992; Kalsbeek et al., 1993) . Colocalization of mRNA and protein immunoreactivity (-ir) for GRP,_,,, PHI, and VIP have been demonstrated in some cells in the ventrolateral aspect of the rat SCN (Okamura et al., 1986; Albers et al., 1991) . High levels of receptor mRNA and high grain densities of binding sites for these peptides have also been demonstrated in the rat SCN (Shaffer and Moody, 198.5; Besson et al., 1986; Martin et al., 1987; Moody et al., 1988; Ladenheim et al., 1990 Ladenheim et al., , 1992 Ladenheim et al., , 1993 Battey and Wada, 1991; Hill et al., 1994; Usdin et al., 1994) , implicating their local release in the modulation of neuronal activity in the rat SCN. However, the functional correlates of this colocalization are unknown.
A previous report claimed that GRP,,,, PHI, and VIP interact synergistically to produce maximal postsynaptic effects on SCN cellular activity and function (Albers et al., 1991) . Individually, GRP,_,,, PHI, or VIP evoked only small activations in hamster SCN neuronal activity in vitro, while a cocktail containing equimolar doses of all three of these neuropeptides induced large increases in the spontaneous firing rate. In parallel investigations, microinjections of GRP,-,,, PHI, or VIP alone into the SCN of hamsters free running in constant, bright light (LL) conditions produced only small phase shifts in the locomotor activity rhythm, while microinjection of the neuropeptide cocktail produced very large phase delays. These studies indicate that GRP,_,,, PHI, or VIP alone have minimal effects on rodent SCN neuronal activity, but their collective interaction produces maximal effects on the circadian pacemaker. These results have been cited frequently as providing critical support for a model which proposes that colocalization and co-release of these peptides are essential for them to play their functional role in the entrainment of circadian rhythms (Albers et al., 1991; Peters et al., 1994) .
Attempts to replicate these neurophysiological results have not, however, been successful. A number of studies have found that GRP,_,, alone can potently alter rodent SCN neuronal activity in vitro. Bath applications of GRP,-,, depolarized rat SCN cells, while local applications of GRP,-,, (and related analogs) by pressure ejection or iontophoresis activated hamster SCN cells (Piggins and Rusak, 1993a; Tang and Pang, 1993; Piggins et al., 1994b; Pinnock et al., 1994) . The effects of GRP,-,, analogs on rodent SCN cells appear to be specific and receptor mediated, since they were blocked or attenuated by GRP-preferring receptor antagonists. Since these results contradicted the earlier claim in showing that GRP,_,, alone has large effects on rodent SCN cells, it became important to reexamine the proposed functional interactions among these peptides.
We have therefore reexamined the hypothesis that GRP,-,,, PHI, and VIP interact to exert a maximal effect on the hamster circadian pacemaker. We did this by first examining the phaseshifting properties of GRP,_*i, since this neuropeptide has been shown to be a potent activator of both rat and hamster SCN cells (Piggins and Rusak, 1993a; Tang and Pang, 1993; Piggins et al., 1994b; Pinnock et al., 1994) . We then assessed the phase-shifting effects of PHI and VIP when administered alone or in combination with GRP,-,,. In the first series of experiments, we established a phase-response curve for GRP,-,,, and showed dose relatedness of GRP,-,, -induced phase delays, blockade of these phase delays with a GRP,-,, receptor antagonist, and the independence of GRP,,,-induced phase shifts from injection volume or constant lighting conditions. In the second series of experiments, we evaluated the phase-shifting effects of PHI and VIP alone at two phases of the circadian cycle and the influence of constant lighting conditions on these phase shifts. We then compared the phase-shifting effects of GRP,-,,, PHI, or VIP alone with the phase-shifting effects of a neuropeptide cocktail containing equimolar doses of all three of these neuropeptides.
Some of these results have been presented previously in abstract form (Piggins and Rusak, 1993b; Piggins et al., 1994a) .
Materials and Methods
Animals. Adult male Syrian hamsters (LVGlak) were obtained from Charles River Canada (St. Constant, Quebec, Canada) and housed (with ad lib access to standard lab chow and water) in a colony room for at least 10 d on a 24 hr 1ight:dark cycle (LD 14:lO) at a room temperature of -20°C. Animals were then transferred to test rooms equipped with cages containing running wheels and maintained in one of the following lighting conditions: constant dim red light (RR; illumination from a 10 W safelight equipped with either a Kodak GBX or GBX2 filter; light intensity at the center of the room < 0.1 lux); constant bright light (LL; illumination from a pane1 of Daylight fluorescent tubes; light intensity at the center of the room -300 lux); or constant dark (DD; 0 lux).
Animals were allowed to free run under these conditions for l-2 weeks. Each animal (n = 235) was then implanted stereotaxically with a 22 gauge stainless steel cannula (Plastics One, Roanoke, VA) cemented to the skull with dental acrylic under sodium pentobarbital anesthesia (80 mg/kg). The cannula was aimed at the SCN region [coordinates (adjusted slightly for body weight) 0.5 mm anterior to bregma, 0.2 mm lateral to the midline, and 7.3 mm ventral to the skull surface; incisor bar at -2.0 mm]. An obtruder (29 gauge) was inserted to extend 1.0 mm beyond the tip of the external guide cannula. Animals were injected with the analgesic buprenorphine (0.5 mg/kg) following recovery from the anesthetic.
GRP,_,, (Bachem, Torrance, CA) or BIM 26226 (a gift of Dr. John Taylor, Biomeasure Inc., Milford, MA) was dissolved in physiological saline and injected through a 30 gauge stainless steel inner cannula, which was inserted to extend 1 mm below the end of the guide cannula. A volume of up to 1 .O ~1 of either saline vehicle or GRP,-,, (up to 150 pmol) was injected using a 0.5 or 1.0 (*l Hamilton syringe and PE20 tubing. Animals were injected repeatedly at different circadian phases using either drug or vehicle as long as they maintained stable freerunning rhythms (ranging from one to nine injections, with an average of four). Some animals contributed data to more than a single study, although each was maintained and tested in only one constant lighting condition.
In the first experiment, drug or vehicle solutions were injected at various phases of the circadian cycle to assess circadian variation in sensitivity to GRP,_,, and saline vehicle, as reflected in the phase-response curves (PRCs) that were constructed. In a second experiment, several features of the phase-delaying effects of GRP,-,, were assessed: (1) A dose-response curve was generated for the phase-delaying effects of GRP, 17 bv iniectina 1 I.L~ of saline containinrr 0. -14) . (3) The specificity of the pharmacological effects of GRP,-,, at CT12-14 was assessed by injecting either the BN/GRPpreferring receptor antagonist BIM 26226 (500 pmol in 0.5 p,l) or saline vehicle 10 min urior to iniection of either GRP, ,, (50 omol in 0.5 ul) or saline vehicle during CT12-14.
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Since these studies were conducted in different lighting conditions from those used by Albers et al. (1991) , the effects of constant lighting conditions on GRP,-,, -induced phase shifts were assessed in a third experiment. We compared the effects of GRP,_,, microinjections in RR in the first study to the effects of similar treatments on animals housed in LL, to allow comparison to the study by Albers et al. (1991) . In addition, in order to ensure that any effects observed were not the result of interactions of the drug with the very dim red light or the bright white light, we repeated the study using hamsters housed in total darkness (DD). Animals in LL were injected with 0.5 ~1 saline, either alone or containing 50 or 150 pmol of GRP,_,, at CT4-8, CT12-14, or CT20-24. Animals in DD were tested with saline or 150 pmol of GRP,-,, in 0.5 p,l saline at CT12-14 or CT20-24 only, since these were the phases at which the largest shifts were induced. Injections of animals in RR and DD were performed with the aid of a head-mounted infrared source and viewer (FJW Industries, Mt. Prospect, IL).
In the fourth experiment, we examined the proposition that GRP,_,,, PHI, and VIP interact synergistically to exert a maxima1 effect on the hamster circadian pacemaker. We tested this hypothesis by studying the phase-shifting effects on rhythms of microinjections of GRP,_,,, PHI, and VIP, administered alone or in a neuropeptide cocktail. As in the single-peptide studies, one group of animals was tested in DD while another group was tested in LL to allow a direct comparison with the Albers et al. (1991) study. Animals were injected with one of the peptides (50 or 150 pmol dissolved in 0.5 pl saline), an equimolar neuropeptide cocktail containing 50 pmol of each neuropeptide, or vehicle alone at CT12-14 or 20-24. Injections of animals in DD were performed with the aid of the infrared viewer.
Analysis ofphase shifts. Phase shifts were assessed using the line of best fit method (Daan and Pittendrigh, 1976) . Briefly, activity was recorded as raster displays generated both from event recorders and a computerized data acquisition system. A line was fitted visually along the activity onsets (=CT12) for 7-10 d prior to an injection and extrapolated to predict the onset of activity on the day following an injection. Discounting 2-3 d of transient cycles, a line was then fitted through the activity onsets for 7-10 d of stable rhythmicity following Phase Shifi Circadian Rhythms the injection, and extrapolated back to the day following the injection. The horizontal difference between the predicted onsets was measured and converted to yield the phase shift in minutes. Phase shifts were rated independently by two experienced observers (one blindly, with respect to treatment) and their assessments averaged. In the case of a discrepancy >lO min between the observers' ratings, the phase shift was rated a second time by both observers and a consensus reached. The observers' assessments were compared using a subset of the data, and the correlation between their ratings was 0.93. If activity onsets were highly irregular either before or after a treatment, the data related to that treatment were discarded.
Phase shifts were analyzed using analyses of variance followed by planned comparisons tests between individual means (1 df) or TukeyKramer post hoc tests, where appropriate. Significance in all cases was defined as p < 0.05. Phase shifts were considered to be greater than 0 when the calculated 95% confidence intervals for a mean value did not overlap the 0 value. Statistical analyses were performed using SUPER-ANOVA on a Macintosh computer.
Histological analysis. At the conclusion of the experiment, hamsters were deeply anesthetized with an intraperitoneal injection of sodium pentobarbital, and perfused intracardially with 50 ml of 165 mM NaCl followed by 100 ml of 10% formalin. Brains were removed, postfixed for 48 hr, and cut on a cryostat into 40 km coronal sections. Sections were stained with Cresyl violet and examined to identify the location of the cannula tips. Tip placements were classified according to their approximate distance from the external border of the SCN; data from animals with tips >600 p,rn from the external border of the SCN were excluded from further analysis. . Phase-shift data were grouped into 4 hr bins and analyzed with a two-way ANOVA. There was no main effect of drug, but there was a significant main effect of circadian time (F5,,,9 = 10.67, p < 0.0005) and a significant CT X drug interaction Vu,9 = 5.65, p < 0.0005). GRP,,, effects were phase dependent: there were no differences between the effects of saline and GRP,-2, injections at some circadian phases, but there were significantly larger phase delays induced by GRP,-,, than by saline at CT12-16 (df = 1, F = 17.58, p < O.OOl), and significantly larger phase advances at CT20-24 (df = 1, F = 8.65, p < 0.005) (Fig. 3) . Examination of the 95% confidence intervals for the mean phase shifts induced in different 4 hr intervals indicated that both saline and GRP,_,, caused phase shifts greater than 0 min at CT8-12 and 12-16, but the average saline-induced shifts were very small at these phases (delays of 14.3 and 9.3 min, respectively). GRP,_,, also caused phase shifts greater than 0 min at CT20-24, while saline did not. To examine this phase dependence in more detail, data were grouped into 2 hr bins. GRP,_,, caused the largest average phase delays at CT12-14 (66.4 + 11.7 min; mean ?Z SEM), and the largest phase advances at CT22-24 (78.4 t 33.9 min); saline injections caused average .delays of 12.5 2 3.5 min and advances of 6.8 + 4.5 min at these phases. The results of a one-way ANOVA indicated that injection volume had no significant effect on GRP,-,,-induced phase delays (F,,,, = 0.5 1, p > 0.05). The magnitude of the mean delay shifts varied from a minimum of 39.7 + 10.4 min at the 0.25 p,l volume to a maximum of 60.3 t 13.1 min at the 0.06 ~1 volume, but no significant differences were found when individual means were compared post hoc with the Tukey-Kramer test (p > 0.05 for all comparisons).
A one-way ANOVA was used to assess the effects of pretreatment with the BN/GRP receptor antagonist BIM 26226 or saline on phase shifts induced by subsequent injection of GRP,-2,. There was a significant effect of drug treatment (F,,,, = 13.624, p < 0.005) on phase shifts induced by paired injections of saline, GRP,_,,, and BIM 26226 at CT12-14. Phase delays induced by injections of saline followed by GRP,-,, (50 pmol in 0.5 ~1) at CT12-14 averaged 65.7 +-4.0 min. These shifts were significantly attenuated when the BN/GRP-preferring receptor antagonist BIM 26226 (500 pmol in 0.5 pl) was given prior to the GRP,-,, injection (mean delay: 23.9 2 9.9 min; df = 1, F = 16.242, p < 0.001) (Figs. 5, 6 ). Paired injections of BIM 26226 followed by saline caused similar small phase delays (25.3 ? 3.9 min), while the pairing of saline followed by saline caused very small phase delays (13.0 2 6.9 min). Planned comparisons indicated that the shifts induced by the combinations BIM 26226/GRP,m,,, BIM 26226/saline, and saline/saline did not differ significantly 01 > 0.05).
Experiment 3: effects of lighting conditions
In LL, microinjections of GRP,_,, (50 or 150 pmol in 0.5 ~1) in the SCN region of hamsters induced phase shifts which differed from 0 min at CT12-14 and CT20-24 but not at CT4-8 (Figs. 7, SB). A two-way ANOVA was used to compare the effects of the drug and saline injections at the three circadian phases tested. There was no significant main effect of drug, but there was a significant main effect of circadian phase (F2,54 = 30.13, p < 0.005), and a significant drug X circadian phase interaction (F3,54 = 9.91, p < 0.0005). GRP,_,, (50 pmol) induced significantly larger phase shifts at CT12-14 than did saline (46.13 + 7.4 vs 10.5 + 6.1 mm delays; df = 1, F = 7.29, p < 0.01) and larger phase advances at CT20-24 (31.38 -t 11.3 min advance vs a 7.6 + 6.6 min delay for saline; df = 1, F = 10.58, p < 0.005). Similarly, GRP,,, at the high dose (150 pmol) induced significantly larger phase delays (57.6 2 14.14 min) than saline at CT12-14 (df = 1, F = 11.84, p < O.OOS), and significantly larger phase advances (35.0 2 10.75 min) at CT20-24 (df = 1, F = 13.47, p < 0.001).
Hamsters were also tested in DD for the effects on phase of microinjections of GRP,_,, (150 pmol in 0.5 pl) into the SCN region (Fig. 8A) . A two-way ANOVA on phase shifts induced by saline or GRP,_,, at two circadian phases indicated significant main effects of drug (F,,2, = 10.43, p < 0.005) and circadian phase (F,,,, = 178, p < O.OOOS), and a significant drug X circadian phase interaction (F,,,, = 135, p < 0.0005). GRP,,, induced significantly larger phase delays than did saline at CT12-14 (72.9 -+ 5.8 vs 1.6 t 3.9 min; df = 1, F = 123.86, p < O.OOOS), and significantly larger phase advances at CT20-24 (47.0 + 5.0 vs 6.7 ? 2.8 min; df = 1, F = 31.79, p < 0.0005).
The mean phase shifts induced by GRP,-,, at two circadian Circadian Bin phases (CT12-14 and CT20-24) were compared across the three lighting conditions (RR, LL, and DD) using a two-way ANO-VA. There was no significant main effect of lighting condition nor any significant interaction of lighting conditions with phase Vi,, , = 0.27, p > 0.05); the direction and amplitude of the shifts induced by GRP,-,, at these phases were independent of lighting condition.
Experiment 4: effects of coadministration of GRP,_,,, PHI, and VIP
A three-way analysis of variance was used to evaluate the phase shifts evoked by the 150 pmol doses of GRP, PHI, and VIP alone as well as the equimolar peptide cocktail at CT12-14 and CT20-24 under LL or DD. The overall peptide X time X constant lighting condition interaction was not significant (F4,,37 = 0.149, p > 0.05), but the peptide X time interaction was highly significant (F4.,37 = 9.35, p < O.OOOS), as was the main effect of time (F, ,17 = 133.1, p < 0.0005). The peptide X constant lighting condition interaction, time X constant lighting condition interaction, and main effects of peptide and constant lighting condition were all nonsignificant (p > 0.05). The phase shift data were subsequently collapsed across constant lighting conditions, and mean phase shifts compared using planned single degree of freedom tests (Fig. 9) . At CT12-14, 150 pmol GRP,-,, evoked the largest average phase delay (60.5 * 10.3 min), which was significantly larger than the phase delay due to vehicle (4.5 t 2.6 min) (df = 1, F = 24.4, p < 0.0005) or PHI (150 pmol; 34.5 -t 8.5 min) (df = 1, F = 5.16, p < 0.05). PHI evoked a significantly larger phase delay than vehicle (df = 1, F = 5.3, p < 0.05), as did 150 pmol VIP (33.9 ? 6.2 min; df = 1, F = 5.4, p < 0.05). The equimolar peptide cocktail evoked a large phase delay (50.9 + 10.0 min) which was significantly larger than the delay due to vehicle (df = 1, F = 14.6, p < 0.0005). No other significant differences were detected using single degree of freedom comparisons. At CT20-24, VIP evoked a moderate phase advance (42.2 % 11.8 min) which was significantly larger than the phase advance induced by vehicle (2.0 t 4.5 min) (df = 1, F = 10.1, p < 0.005) or PHI (10.2 -t 5.3 min) (df = 1, F = 5.6, p < 0.05). The equimolar cocktail induced a moderate phase advance (38.1 +-8.4 min) which was significantly larger than the phase advance induced by vehicle (df = 1, F = 10.6, p < 0.005) or PHI (df = 1, F = 5.5, p < 0.05). GRP evoked a moderate phase advance (33.3 -C 4.9) which was significantly larger than the phase advance to vehicle (df = 1, F = 6.9, p < 0.01). No other significant differences were detected using single degree of freedom comparisons.
Under DD only, some animals were also injected with 50 pmol doses of GRP,_,,, PHI, and VIP as well as the equimolar (150 pmol) peptide cocktail at CT12-14. One-way analysis of variance indicated a significant effect of drug type on phase shifts (F,,,, = 5.58, p < 0.005). The equimolar (150 pmol) cocktail evoked the largest phase delay (59.3 2 13.0 min), which was significantly larger than phase delays evoked by 50 pmol PHI (20.7 2 8.3 min) (df = 1, F = 6.7, p < 0.05), 50 pmol VIP (18.3 t-7.1 min) (df = 1, F = 8.3, p < O.Ol), or saline (1.2 2 3.0 min) (df = 1, F = 19.2, p < 0.0005). GRP,-,, (50 pmol) evoked a moderate phase delay (42.4 -C 13.9 min) that c I I
Time of Day (hr) Figure 6 . Double-plotted wheel-running activity records of a hamster free running in constant dim red light. Phase-shifting effects of the following sequences of microinjections at CTl2-14 are shown: BIM 26226 (500 pmol)lGRP,_,, (50 pmol) (+-I), saline/GRP,-,, (t2), BIM 26226kaline (t3), or saline/saline (t4).
was significantly larger than the phase delay due to injection of saline vehicle (df = 1, F = 8.0, p < 0.01). The phase shift evoked by microinjections of the peptide cocktail (150 pmol) did not differ significantly from the phase delay induced by GRP,-,, (50 pmol: p > 0.05), and no other significant differences Circadian Time between treatments were found using single degree of freedom comparisons.
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These results do not support the contention that the apparently colocalized neuropeptides, GRP,-,,, PHI, and VIP, must function collectively in order to exert maximal effects on the circadian pacemaker in the hamster SCN. These data are also inconsistent with the suggestion that these neuropeptides individually have little effect on SCN activity; rather, they clearly demonstrate that each neuropeptide can phase shift the circadian pacemaker. GRP,-m is the most potent phase-delaying agent and has mod-H : : -erate phase-advancing potency; VIP is a modest phase-delaying and an effective phase-advancing agent; and PHI is a moderate phase-delaying agent only, while vehicle had few effects at any point of the circadian cycle. Coinjection of PHI, VIP, and GRP,,, to a total of 150 pmol gave no evidence of synergism. Instead, the 150 pmol cocktail caused phase shifts that were marginally smaller than those induced by 150 pmol of GRP,,, alone, and considerably smaller than even a simple addition of the effects of the constituent 50 pmol peptide doses would predict. do 14
Time of Day (hr) GRP,-,, (150 pmol) induced significant phase shifts when microinjected into the SCN of free-running hamsters in the early and late subjective night. When collapsed across lighting conditions in experiments 1-3, phase delays at CT12-14 averaged 66 min and phase advances at CT20-24 averaged 43 min, while delays and advances averaged 61 min and 33 min, respectively, at these phases in the fourth experiment. The magnitudes of these average phase shifts were unaffected by constant lighting conditions, indicating that these lighting regimes do not alter the sensitivity of hamster SCN cells to GRP,-,,. GRP,_,,-induced phase delays were unaffected by injection volume and showed a degree of dose relatedness. Most importantly, phase delays induced by 50 pmol GRP,-,, were attenuated by pretreatment with BIM 26226, indicating that these effects were apparently mediated via the GRP-preferring receptor subtype. These results are consistent with data from neurophysiological studies which indicated that GRP,_,, and GRP analogs potently activated rodent SCN cells in vitro (Piggins and Rusak, 1993a; Tang and Pan, 1993; Pinnock et al., 1994) and that these neurophysiological effects were also blocked by the GRP-preferring receptor antagonist BIM 26226 (Piggins et al., 1994b) . In addition, the phase of the circadian cycle at which GRP,-,, delays the circadian pacemaker in vivo corresponds to the phase of the projected circadian cycle at which a larger percentage of hamster SCN cells in vitro are responsive to GRP analogs (Piggins et al., 1994b) . Since these effects are apparently mediated by the GRP-preferring receptor subtype, these data may suggest that increased numbers of this receptor are available in the SCN at 1990; Huang and Rorstad, 1990; Usdin et al., 1994) , a change in receptor affinity state during the night may account for the difference in the phase-advancing potencies of these peptides at CT20-24 despite their very similar effects at CT 12-14. Overall, these data indicate that PHI and VIP phase shift the hamster circadian pacemaker through an as yet uncharacterized mechanism. The equimolar neuropeptide cocktail (150 pmol) phase shifted hamster locomotor activity rhythms in the same direction as did 150 pmol injections of GRP,-,,, PHI, and VIP when administered individually. When the data from the fourth experiment were collapsed across constant lighting conditions, the apparent rank order of phase-delaying potency at CT12-14 was GRP,_,, (61 min) = cocktail (51 min) > PHI (35 min) = VIP (34 min) > saline (4.5 min). At CT20-24, the apparent rank order of phase-advancing potency was VIP (42 min) = cocktail (38 min) = GRP,_,, (33 min) > PHI (10 min) = saline (2.0 min). The phase shifts induced by the equimolar neuropeptide cocktail were not significantly greater than those to GRP,_,, or VIP, but were larger than PHI alone at CT1 2-14 and CT20-24. When tested in DD, phase delays induced by the cocktail at CT12-14 were less than the summed effects of individually administered 50 pmol doses of GRP,-,, + PHI + VIP (58 vs 82 min, respectively), and not significantly greater than the phase delay to GRP,_,, (50 pmol) alone (42 min). Since the phase-shifting effect of the cocktail was less than the summed effects of the 50 pmol doses of the peptides, these data indicate a lack of synergism among the effects of these peptides. Further, because GRP,_,, (150 pmol) evoked shifts similar in magnitude to those of the cocktail, the data do not support the hypothesis that these apparently colocalized neuropeptides must interact to exert maximal effects on the circadian pacemaker.
These results generally contrast with those of a previous study in which GRP,_,,, PHI, and VIP individually induced only small to moderate phase delays, whereas an equimolar cocktail evoked very large delays in the activity rhythms of hamsters free running in constant bright light (Albers et al., 1991) . These discrepancies are difficult to resolve. The data from the GRP,_,, studies indicate that injection volume is probably not a critical variable, and the volume used in most of our experiments (0.5 ~1) is comparable to the 0.4 ~1 used previously (Albers et al., 1991) . Other methodological differences include the gauge of cannula used and stereotaxic coordinates for implantation, which might affect the amount of peptide that penetrates to the SCN.
If our method caused larger amounts of peptides to reach the SCN, one might expect consistently larger shifts in this study. Although we found much larger shifts to GRP than were reported by Albers et al. (1991) , both reports describe comparable delay shifts to PHI and comparable advance shifts to the peptide cocktail using the same nominal doses. This makes it unlikely that differences in methods caused consistently different amounts of peptide to reach the SCN. In addition, we saw little change in shift amplitude in response to GRP doses ranging from 16.7 to 150 pmol, so even a IO-fold reduction in peptide delivery to the target using a nominal 150 pmol dose should not have greatly reduced the amplitude of phase shifts.
An alternative explanation is that the smaller sample sizes studied by Albers et al. (1991) produced average results that do not adequately reflect the population means for these treatments. The claim that GRP,_,, alone does not produce substantial shifts in the early subjective night (<30 min) was based on a sample of nine injections (Albers et al., 1991) . Injections at this time CT12-16. Overall, these results indicate that GRP,,, potently and robustly resets the circadian pacemaker with a temporal pattern similar to that of light, apparently by its interaction with the BN/GRP-preferring receptor subtype. VIP (150 pmol) induced moderate phase delays at CT12-14 (34 min) and moderate phase advances at CT20-24 (42 min). PHI (150 pmol) evoked moderate phase delays at CT12-14 (35 min) but only small phase advances at CT20-24 (10 min). At CT20-24, VIP (150 pmol) was a more potent phase-advancing drug than PHI. Phase shifts evoked by PHI and VIP were independent of the constant lighting conditions, suggesting that ambient illumination does not alter sensitivity of the hamster SCN to these peptides. The influence of VIP and PHI on hamster SCN neuronal activity has not been examined extensively, but the data of Aibers et al. (1991) indicate that both peptides can increase SCN cell firing rates.
The mechanism mediating the effects of these peptides on the hamster SCN is unknown. High grain densities of '2sI-VIP binding sites are present in the rat and hamster SCN (Diet1 et al., 1990; Robinson and Fuchs, 1993; Hill et al., 1994) , and recent in situ hybridization results show intense expression of mRNA for the VIP, receptor in the rat SCN (Usdin et al., 1994) . Since PHI has less affinity than VIP for VIP receptors (Cauvin et al., yielded consistent effects in all of our studies, and our mean of about 64 min reflects results from 51 animals. The claims that the peptide cocktail does not cause substantial phase advance shifts and that the cocktail has larger delaying effects than any single peptide were assessed in Albers et al. (1991) using group sizes of 7-11 animals and no vehicle control injections. In our fourth experiment, we used 12-22 injections for each condition and compared our results to those of vehicle-treated controls. We observed considerable variability in phase shifts to single peptides even with these larger sample sizes (e.g., GRP,-,, (150 pmol) at CT12-14 induced a mean phase delay of approximately 61 min, with a range of O-215 min; n = 22). Given this degree of variability with a only a single peptide, and the additional complications of coinjecting three peptides, a large sample size may be critical to obtaining reliable results.
In both the rat and hamster SCN, cell bodies containing PHI/ VIP and GRP,_,, are found in areas which are innervated by the RHT Electron microscopic studies indicate that at least VIPcontaining cells are contacted by retinal afferent terminals (Okamura et al., 1987; Ibata et al., 1989) . Light induces immediateearly gene expression in GRP,-,,-and PHI/VIP-containing rat SCN cells at the same phases of the circadian cycle at which it can phase shift the circadian pacemaker (Earnest et al., 1993; . These results imply that the effects of light on the retina are conveyed directly to these peptidergic cells in the rodent SCN, and that the local release of these neuropeptides might be involved at some level of the photic entrainment mechanism. Our results support this interpretation: when administered alone or in combination, GRP,-,,, PHI, and VIP phase shift circadian rhythms at the same phases and in the same direction as do light pulses (Daan and Pittendrigh, 1976; Takahashi et al., 1984) . These neuropeptides may play a role in photic entrainment, but the nature of this putative involvement will require further study.
GRP,_,, and VIP levels in the rat SCN do not show circadian fluctuations in constant conditions but are differentially affected by light. GRP,-,, levels in the rat SCN are increased by light while VIP levels are decreased (Shinohara et al., 1992) . When maintained under a 12: 12 LD cycle mRNA levels for these peptides also show diurnal variation, with GRP,_,, mRNA being high early in the day and low at night, while mRNA for VIP is high at night and low during the day (Zoeller et al., 1991) . These data indicate that light differentially affects GRP,-,, and VIP levels in the rat SCN. Since PHI and VIP are products of the same precursor and are probably colocalized throughout most of the rodent SCN, it seems likely that PHI levels are altered by light in a similar way. Immunocytochemical research has shown GRP,-2, and PHI to be colocalized in some cells of the rat SCN (Okamura et al., 1986) . Together, these observations imply that fluctuations in GRP,-,, and VIP (and presumably PHI) levels in axon terminals can give rise to different ratios of presynaptic release of these neuropeptides, resulting in different postsynaptic effects. Albers et al. (199 1) proposed that the larger the ratio of release of GRP,_,, to PHI/VIP early in the subjective night, the greater the phase delay induced, while the larger the ratio of release of PHI/VIP to GRP,,, in the late subjective night, the greater the phase advance (see Peters et al., 1994) . While our results suggest that GRP,-,, is the most potent phase-delaying agent among these peptides, they are otherwise inconsistent with this model. The magnitude of the phase delay evoked by GRP,-2, (150 pmol) alone at CTl2-14 is very similar to that caused by the equimolar cocktail, while the dosage ratios of GIG'-,,: PHI/VIP are radically different in the two conditions. Furthermore, the magnitude of the phase advance induced by VIP (150 pmol) alone at CT20-24 is very similar to that of the equimolar cocktail at this circadian phase despite the radically different peptide ratios involved. These results demonstrate that an interaction among these neuropeptides is not a significant factor determining their phase-shifting efficacy. Further experimentation will be required to explore the possible interactions of these peptides, but the present data suggest redundancy in peptidergic mechanisms putatively involved in phase shifting the circadian pacemaker.
Other results also call into question the potential for functional interactions among GRP,_,,, PHI, and VIP in the regulation of the mammalian circadian pacemaker. Anatomically, the extent of GRP,-,,/PHI colocalization in the rat SCN has been estimated to be modest. Many GRP,-,,-ir perikarya are located more laterally than PHI/VIP-ir cell bodies in the rat SCN, and GRP,-,,-ir and VIP-ir fibers project in different patterns (Okamura et al., 1986; Okamura and Ibata, 1994) . In addition, even the demonstration of mRNA for both GRP,-,, and PHI/VIP in a single neuron does not necessarily imply functional co-release or even colocalization in individual axon terminals. These peptides may be processed and distributed differentially to different terminal regions of a single neuron (e.g., Okamura and Ibata, 1994) . In the hamster SCN, GRP,-,,-immunostained cell bodies overlap to a small extent with PHI/VIP immunopositive perikarya, but the overall distribution of immunostained cell bodies for these peptides is different (Piggins, Semba, and Rusak, unpublished observations) , and it has yet to be established whether GRP,_,, and PHI/VIP are actually colocalized to any extent in the SCN of this species. Discussion of the effects of co-release of PHI/VIP and GRP,_,, in hamsters is premature in the absence of data indicating their colocalization.
A number of other issues require further investigation before the neurochemistry of peptides in the rodent SCN can be accurately modeled. First, precursors for GRP,-,, and PHI/VIP can be cleaved into other peptide molecules, the role of which has not been assessed and could complicate any model of interactions among the larger peptides. The presence of these fragments has been demonstrated in the rodent SCN (Mikkelsen et al., 1991; Mikkelsen and Fahrenkrug, 1994) , and at least one (GRP,,-,,) potently activates hamster SCN cells in vitro (Piggins et al., 1994) . Second, implicit in the ratio model is the assumption that receptors for GRP,-,, and PHI/VIP are expressed in the same cell populations in the SCN, but there is no conclusive evidence about the availability, distribution, or even coexpression in single SCN neurons of postsynaptic receptors for these neuropeptides. Further research is required to characterize the anatomical and temporal distribution of PHI/VIP-and GRP-preferring receptors in the rodent SCN. Third, a ratio model would have to take account of photic regulation of extra-SCN sources of these peptides which may project to the SCN. In the rat, some retinal ganglion cells synthesize message for PHI/VIP, which may be transported to the SCN (Denis et al., 1993) , and others show GRP,m,, -ir (McKillop et al., 1988) . These results raise the possibility of complex interactions among these and other peptides in the SCN, which are unlikely to be captured by a simple ratio model.
In conclusion, microinjection of GRP,_,,, PHI, and VIP into the SCN region phase delayed hamster locomotor rhythms. GRP,-2, was the most potent phase-delaying peptide, and these The Journal of Neuroscience, August 1995, 15(E) 5621 shifts were dose related up to 16.7 pmol (with an apparent ceiling effect at higher doses). GRP,_,,-induced phase shifts were independent of both constant lighting conditions and injection volume, and apparently mediated via the GRP-preferring receptor subtype. Both GRP,-,, and VIP also phase advanced locomotor rhythms. Coadministration of all three peptides failed to shift rhythms to a greater extent than GRP,_,, or VIP alone. The magnitude of the shifts resulting from coadministration was less than the summed effects of each peptide alone, indicating that the interaction among GRP,_,,, PHI, and VIP was subadditive and not synergistic. Indeed, if PHI and VIP both bind to VIP receptors (Huang and Rorstad, 1990) , their coinjection is likely to generate competitive rather than synergistic effects at the receptor level. Interactions among these peptides were not necessary to produce maximal effects on the circadian pacemaker. Since GRP,_,,, PHI, and VIP alone or in combination shifted locomotor rhythms in the same direction and at the same phases as light does, these peptides may be involved in photic entrainment of the circadian pacemaker. If these peptides are co-released in the rodent SCN, the functional consequences of this mechanism remain unknown.
